Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature

Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID‐19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Bishawi, Ahmad, Abdel Hadi, Hamad, Elmekaty, Eman, Al Samawi, Musaed, Nair, Arun, Abou Kamar, Mohammed, Al Maslamani, Muna, Abdelmajid, Alaaeldin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867201/
https://www.ncbi.nlm.nih.gov/pubmed/35228879
http://dx.doi.org/10.1002/ccr3.5467
Descripción
Sumario:Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID‐19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.

Ejemplares similares